The women's health initiative study: Perspectives and implications for clinical practice

Reviews in Endocrine and Metabolic Disorders

Volumn 6, Issue 2, 2005, Pages 93-99

  Hammond, Charles B ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen; Postmenopausal hormone therapy; Progestin; Women's health initiative

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; PLACEBO;

AGE DISTRIBUTION; BREAST CARCINOMA; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; COLORECTAL CANCER; COLORECTAL CARCINOMA; DEMENTIA; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FOLLOW UP; HEALTH CARE ORGANIZATION; HEART DEATH; HEART INFARCTION; HIP FRACTURE; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INVASIVE CARCINOMA; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MENOPAUSAL SYNDROME; PATIENT MONITORING; POSTMENOPAUSE; PRIMARY PREVENTION; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SCREENING; STATISTICAL SIGNIFICANCE; STROKE; TREATMENT OUTCOME; UNITED STATES; UTERUS BLEEDING; VENOUS THROMBOEMBOLISM;

BODY MASS INDEX; BREAST NEOPLASMS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL INSTITUTES OF HEALTH (U.S.); PLACEBOS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; WOMEN'S HEALTH;

EID: 18044393196     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-005-6721-x     Document Type: Review

References (25)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
2. Women's Health Initiative Steering Committee. The effects of conjugated equine estrogen in postmenopausal women with hysterectomy (The Women's Health Initiative randomized, controlled, trial). JAMA 2004;291:1701-1712.
3. Shumaker SA, Legault C, Rapp SR, Thail, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Study: A randomized controlled trial. JAMA 2003;289:2651-2662.
4. Blake JM, Collins JA, Reid RL, Fedorkow DM, Lalonde AB, Christilaw J, Fortier M, Fortin C, Jolly EE, Lemay A, O'Grady T, Smith TE, Cooper J, Maxted JM, O'Grady K, Turek MA; SOGC (Society of Obstetricians and Gynaecologists of Canada). The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women. J Obstet Gynecol Can 2002;24(10):783-787.
5. Response to the Women's Health Initiative Study results by the American College of Obstetricians and Gynecologists. ACOG.net 2002; August 2002.
6. Schneider, Herman PG. The view of the International Menopause Society on the Women's Health Initiative, 2002.
7. Amended report from NAMS Advisory Panel on Postmenopausal Hormone Therapy. Advisory Panel Report. Menopause 2003;10:6-12.
8. ACOG Statement on the NIH announcement to halt the estrogen-only arm of the WHI study. ACOG.net 2004; March 2004.
9. ASRM Statement on Suspension of the WHI Trial. Infertility Resources, Internet Health Resources 2004; March 2004.
10. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
11. Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, Selzer RH, Liu Cr CR, Liu Ch CH, Azen SP. Estrogen in the Prevention of Atherosclerosis Trial Research Group. Estrogen in the prevention of atherosclerosis: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;35:939-953.
12. Hanke H, Kamenz J, Hanke S, Spiess J, Lenz C, Brehme U, Bruck B, Finking G, Hombach V. Effect of 17-β estradiol on pre-existing atherosclerotic lesions: Role of the endothelium. Atherosclerosis 1999;147:123-132.
13. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct atherogenic effect of estrogen is present, absent or reversed, depending on the state of the arterial endothelium. Circulation 1999;100:1727-1733.
14. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factor in postmenopausal women: The PEPI Trial. JAMA 1995;273:199-208.
15. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-1811.
16. Adams MR, Washburn SA, Wagner JA, Williams JK, Clarkson TB. Aterial changes: Estrogen deficiency and the effects of hormone replacement. In Lobo RA, ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999:377-384.
17. Karas RH, Clarkson TB. Menopausal Medicine 2003;10:9-12.
18. Manson JE, Hsai J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
19. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, Schenck-Gustafsson K, Smith SC Jr, Taubert KA, Wenger NK; American Heart Association. Hormone replacement therapy and cardiovascular disease: A Statement for health care professionals from the American Heart Association. Circulation 2001;104:499-503.
20. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 2001;104(19):2255-2259.
21. Leblanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: Systematic review and data analysis. JAMA 2001;295:1489-1499.
22. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
23. Sherwin BB, Tulandi T. "Add-Back" estrogen reverses cognitive defects induced by GnRH agonists in women with leiomyomata uteri. J Clin Endocrinol Metab 1996;81:2545-2549.
24. Shaywitz SE, Naftolin F, Zelterman D, Marchione KE, Holahan JM, Palter SF, Shaywitz BA. Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen. Menopause 2003;10:420-426.
25. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: The Heart and Estrogen/Progestin Study. Am J Med 2002;113:543-548.